Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of Edsivo (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome

Cambridge, MA – September 25, 2017 -- Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials